Mechanism underlying defective interferon gamma-induced IDO expression in non-obese diabetic mouse fibroblasts

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Hosseini Tabatabaei, Azadeh ^a   Jalili, Reza Baradar ^a   Li, Yunyuan ^a   Kilani, Ruhangiz T ^a   Moeen Rezakhanlou, Alireza ^a   Ghahary, Aziz ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STAT1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE; IDO GENE; IMPAIRED GLUCOSE TOLERANCE; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN CELL;

ANIMALS; COLLAGEN; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; FEMALE; FIBROBLASTS; GENE EXPRESSION; GENES, MHC CLASS I; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN; SPLEEN; STAT1 TRANSCRIPTION FACTOR; TRANSDUCTION, GENETIC; TRYPTOPHAN;

ANIMALIA; MUS;

EID: 84861476079     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037747     Document Type: Article

References (36)

1. Grohmann U, Fallarino F, Puccetti P, (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24: 242-248.
2. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193.
3. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, et al. (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22: 633-642.
4. Bauer TM, Jiga LP, Chuang JJ, Randazzo M, Opelz G, et al. (2005) Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int 18: 95-100.
5. Mellor A, (2005) Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 338: 20-24.
6. Jalili RB, Forouzandeh F, Bahar MA, Ghahary A, (2007) The immunoregulatory function of indoleamine 2, 3 dioxygenase and its application in allotransplantation. Iran J Allergy Asthma Immunol 6: 167-179.
7. Jalili RB, Forouzandeh F, Moeenrezakhanlou A, Rayat GR, Rajotte RV, et al. (2009) Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol 174: 196-205.
8. Tan PH, Bharath AK, (2009) Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases. Expert Opin Ther Targets 13: 987-1012.
9. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, et al. (2003) A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 198: 153-160.
10. Puccetti P, (2007) Commentary: On watching the watchers: IDO and type I/II IFN. European Journal of Immunology 37: 876-879.
11. Liu XQ, Wang X, (2009) Indoleamine 2,3-dioxygenase in tumor induced tolerance. Chin Med J (Engl) 122: 3072-3077.
12. Munn DH, Mellor AL, (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154.
13. Jalili RB, Rayat GR, Rajotte RV, Ghahary A, (2007) Suppression of islet allogeneic immune response by indoleamine 2,3 dioxygenase-expressing fibroblasts. J Cell Physiol 213: 137-143.
14. Jalili RB, Forouzandeh F, Rezakhanlou AM, Hartwell R, Medina A, et al. (2010) Local expression of indoleamine 2,3 dioxygenase in syngeneic fibroblasts significantly prolongs survival of an engineered three-dimensional islet allograft. Diabetes 59: 2219-2227.
15. Sarkhosh K, Tredget EE, Karami A, Uludag H, Iwashina T, et al. (2003) Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG). J Cell Biochem 90: 206-217.
16. Sarkhosh K, Tredget EE, Li Y, Kilani RT, Uludag H, et al. (2003) Proliferation of peripheral blood mononuclear cells is suppressed by the indoleamine 2,3-dioxygenase expression of interferon-gamma-treated skin cells in a co-culture system. Wound Repair Regen 11: 337-345.
17. Sarkhosh K, Tredget EE, Uludag H, Kilani RT, Karami A, et al. (2004) Temperature-sensitive polymer-conjugated IFN-gamma induces the expression of IDO mRNA and activity by fibroblasts populated in collagen gel (FPCG). J Cell Physiol 201: 146-154.
18. Ghahary A, Li Y, Tredget EE, Kilani RT, Iwashina T, et al. (2004) Expression of indoleamine 2,3-dioxygenase in dermal fibroblasts functions as a local immunosuppressive factor. J Invest Dermatol 122: 953-964.
19. Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT, et al. (2006) Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 126: 128-136.
20. Forouzandeh F, Jalili RB, Germain M, Duronio V, Ghahary A, (2008) Skin cells, but not T cells, are resistant to indoleamine 2, 3-dioxygenase (IDO) expressed by allogeneic fibroblasts. Wound Repair Regen 16: 379-387.
21. Schroder K, Hertzog PJ, Ravasi T, Hume DA, (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163-189.
22. Zhou F, (2009) Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28: 239-260.
23. Ting JP, Baldwin AS, (1993) Regulation of MHC gene expression. Curr Opin Immunol 5: 8-16.
24. Ghosh AK, Bhattacharyya S, Mori Y, Varga J, (2006) Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta). J Cell Physiol 207: 251-260.
25. Hassanain HH, Chon SY, Gupta SL, (1993) Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-gamma and-alpha. Analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor. J Biol Chem 268: 5077-5084.
26. Gough DJ, Levy DE, Johnstone RW, Clarke CJ, (2008) IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 19: 383-394.
27. Wang J, Hori K, Ding J, Huang Y, Kwan P, et al. (2011) Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol 226: 1265-1273.
28. Wang Y, Lawson MA, Dantzer R, Kelley KW, (2010) LPS-induced indoleamine 2,3-dioxygenase is regulated in an interferon-gamma-independent manner by a JNK signaling pathway in primary murine microglia. Brain Behav Immun 24: 201-209.
29. Forouzandeh F, Jalili RB, Germain M, Duronio V, Ghahary A, (2008) Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4+ and CD8+ T cells. Mol Cell Biochem 309: 1-7.
30. Anderson MS, Bluestone JA, (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23: 447-485.
31. Stendahl JC, Kaufman DB, Stupp SI, (2009) Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation. Cell Transplant 18: 1-12.
32. Swain SL, (1983) T cells subsets and the recognition of MHC class. Immunol Rev, 74: 129-142.
33. Agaugué S, Perrin-Cocon L, Coutant F, André P, Lotteau V, (2006) 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 177: 2061-2071.
34. Connor TJ, Starr N, O'Sullivan JB, Harkin A, (2008) Induction of indoleamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFNγ? Neurosci Lett 441: 29-34.
35. Chon SY, Hassanain HH, Pine R, Gupta SL, (1995) Involvement of two regulatory elements in interferon- gamma-regulated expression of human indoleamine 2,3-dioxygenase gene. J Interferon Cytokine Res 15: 517-526.
36. Li YY, Tredget EE, Ghahary A, (2004) Cell surface expression of MHC class I antigen is suppressed in indoleamine 2,3-dioxygenase genetically modified keratinocytes: Implications in allogeneic skin substitute engraftment. Human Immunology 65: 114-123.